spesolimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5676	2097104-58-8

Description:

Molecule	Description
Molfile Synonyms: spesolimab spesolimab-sbzo BI 655130 spevigo	Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL-36 alpha, beta and gamma) and downstream activation of pro inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

spesolimab
spesolimab-sbzo
BI 655130
spevigo

Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL-36 alpha, beta and gamma) and downstream activation of pro inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Dec. 9, 2022	EMA	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Sept. 1, 2022	FDA	BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Sept. 26, 2022	PMDA	NIPPON BOEHRINGER INGELHEIM CO., LTD.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC22	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA EPC	N0000194039	Interleukin-36 Receptor Antagonist
FDA MoA	N0000194040	Interleukin-36 Receptor Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004
Generalized pustular psoriasis	indication	238612002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-1 receptor-like 2	Membrane receptor	Q9HB29	ILRL2_HUMAN	ANTAGONIST	Kd	9.65		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4297911	ChEMBL_ID
C000712973	MESH_SUPPLEMENTAL_RECORD_UI
12169	IUPHAR_LIGAND_ID
DB15626	DRUGBANK_ID
019169	NDDF
4041692	VANDF
4041693	VANDF
C5238146	UMLSCUI
10845	INN_ID
D12066	KEGG_DRUG
2610417	RXNORM
361370	MMSL
40858	MMSL
d09913	MMSL
5IB2J79MCX	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SPEVIGO	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0035	INJECTION	60 mg	INTRAVENOUS	BLA	27 sections